Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Hardy Diagnostics Releases HardyCHROM™ Candida + auris

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Hardy Diagnostics announced its release of HardyCHROM™ Candida + auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species.

This medium allows for the identification of C. albicans, C. tropicalis, C. krusei, and the presumptive identification of C. glabrata. Colonies of C. auris will appear white with a characteristic teal to teal-green “bullseye” center. Additionally, C. auris is also differentiated from other Candida species by a unique fluorogenic reaction under UV light.

C. auris is an emerging pathogen that represents a serious multi-drug resistant (MDR) global threat. C. auris may persistently colonize the skin and hospital environment, making its transmission within and between healthcare settings more difficult to control.(1) C. auris results in a wide range of mortality rates depending on the patient’s overall condition, underlying disease, geographic region, access to medical care, and age.(1)

HardyCHROM™ Candida + auris can be used in conjunctions with Rapid Trehalose Broth or GlabrataQuick to aid in the identification of C. glabrata.

Find more information on HardyCHROM™ Candida + auris here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine